Successive Doses of GnRH Agonist Versus Single Dose of GnRH Agonist to Trigger Ovulation in Hyper-responders
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Successive doses GnRH agonist, Single dose GnRH agonist.
- Who it may be relevant to
- Registry conditions: Infertility. Basic parameters: 18 years — 40 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Successive Doses of GnRH Agonist Versus Single Dose of GnRH Agonist to Trigger Ovulation in Hyper-responders Undergoing IVF Cycle : A Randomized Controlled Study.
Overview
The aim of this randomized controlled study is to compare the efficacy of three successive doses of a GnRH agonist ( administered 36 , 24 and 12 hours before oocyte retrieval ) with a single dose of a GnRH agonist ( administered 36 hours before oocyte retrieval ) in triggering ovulation in hyper-responders
Interventions
- Drug Successive doses GnRH agonist
GnRH agonist ( Triptorelin ) ( 0.2 mg / S.C ) is administered 36 hours before ovum pickup. Two additional doses of triptorelin ( 0.1 mg / S.C ) are administered subcutaneously 12 and 24 hours after the first dose of GnRH agonist. - Drug Single dose GnRH agonist
GnRH agonist ( Triptorelin ) ( 0.2 mg / S.C ) is administered 36 hours before ovum pickup.
Primary outcome measures
- Metaphase-II oocytes rate [Time frame: Ten to fifteen days after starting ovarian stimulation]
Secondary outcome measures (2)
- Clinical pregnancy rate [Time frame: Five weeks after embryo transfer]
- Ongoing pregnancy Rate [Time frame: Eighteen weeks after embryo transfer]
Eligibility criteria
Inclusion criteria
- GnRH antagonist IVF cycle
- Hyper-responders to induction of ovulation
Exclusion criteria
- Hypogonadotrophic hypogonadism
- Endometriosis
- History of recurrent abortion
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Bedaya Hospital — Giza
Publications
- Hashemi SH, Hafezi M, Arabipoor A, Zareei M, Vesali S, Eftekhari-Yazdi P. Can We Harvest More Mature Oocytes by Repeating Gonadotropin-Releasing Hormone Agonist Doses in Polycystic Ovarian Syndrome Patients at Risk of OHSS in Antagonist Cycles? A Randomised Clinical Trial. Int J Fertil Steril. 2024 Jul 13;18(Suppl 1):48-54. doi: 10.22074/ijfs.2023.2008905.1513. PMID 39033370
Identifiers
NCT: NCT07569315 · Successive/Single GnRH agonist